Table 1. Demographic and clinical data from of the final study population (N = 91).
| Median | Range | |
|---|---|---|
| Male (N) | 50 | |
| Age (Years) | 53 | 20–81 |
| BMI (kg/m2) | 26.4 | 16.9–35.0 |
| Bilirubin (μmol/L) | 11 | 4–48 |
| AST (μkat/L) | 0.75 | 0.29–4.50 |
| ALT (μkat /L) | 1.10 | 0.19–9.10 |
| ALP (μkat /L) | 1.20 | 0.43–10.00 |
| Fibrosis Stage | ||
| F0 | 29 | |
| F1 | 16 | |
| F2 | 25 | |
| F3 | 14 | |
| F4 | 7 | |
| Diagnosis | ||
| Normal | 8 | |
| NAFLD | 35 | |
| HCV | 8 | |
| PSC | 13 | |
| PBC | 4 | |
| AIH | 12 | |
| AIH-PSC overlap | 2 | |
| AIH-PBC overlap | 1 | |
| Hemochromatosis | 1 | |
| DILI | 2 | |
| Wilson´s disease | 1 | |
| ALD | 2 | |
| AAT deficiency | 1 |
BMI body mass index, AST aspertate aminotransferase, ALT alanine aminotransferase, ALP alkaline phosphatase, NAFLD non-alcoholic fatty liver disease, HCV hepatitis C virus infection, PSC primary sclerosing cholangitis, PBC primary biliary cirrhosis, AIH autoimmune hepatitis, DILI drug induced liver injury, ALD alcoholic liver disease, AAT deficiency α1-antitrypsin deficiency.